Anti-VEGF drugs, as the cornerstone for neovascular glaucoma (NVG), effectively regress iris neovascularization and reduce intraocular pressure (IOP), with aflibercept achieving an 86.7% regression rate and a 12.3 mmHg IOP reduction in clinical trials. The gene discussed is VEGFA; the disease is neovascular glaucoma.